{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-001166","form_type":"8-K","ticker":null,"cik":"0001792581","company_name":"Kiromic Biopharma, Inc.","filed_at":"2024-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.551409+00:00","generated_at":"2026-06-06T02:31:39.696359+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kiromic BioPharma issues $2M 25% senior secured convertible note due Feb 2025","bullets":["Principal $2,000,000, interest 25% p.a. (27% upon default), matures Feb 12, 2025.","Convertible at $2.50/share into common stock (KRBP), subject to 9.99% beneficial ownership cap.","Note is senior secured; collateral includes all fixtures, equipment, and intellectual property.","Issued to an accredited investor in reliance on Section 4(a)(2) exemption."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-001166","json":"https://secwatch.observer/filing/0001558370-24-001166.json","markdown":"https://secwatch.observer/filing/0001558370-24-001166.md","text":"https://secwatch.observer/filing/0001558370-24-001166.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1792581/000155837024001166/0001558370-24-001166-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1792581/000155837024001166/krbp-20240212x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T02:31:39.696359+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"695b6178c35393b5f00d7a4da31772657eab9560","claim":"Kiromic Biopharma, Inc. incurred convertible notes of $2,000,000 with an accredited investor at 25% per annum maturing February 12, 2025.","evidence_excerpt":"On February 12, 2024, Kiromic BioPharma, Inc. (the \"Company\") issued a 25% Senior Secured Convertible Promissory Note (the \"Note\") to an accredited investor. The Note has a principal amount of $2,000,000, bears interest at a rate of 25% per annum (the \"Stated Rate\") and matures on February 12, 2025 (the \"Maturity Date\"), on which the principal balance and accrued but unpaid interest under the Note shall be due and payable.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792581/000155837024001166/0001558370-24-001166-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$2,000,000"},{"label":"Counterparty","value":"an accredited investor"},{"label":"Rate","value":"25% per annum"},{"label":"Maturity","value":"February 12, 2025"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"d473d8a20ac0bfc271c817fbbd0e5d760c9fb478","claim":"Kiromic Biopharma, Inc. entered into 25% Senior Secured Convertible Promissory Note with an accredited investor valued at $2,000,000 (effective 2024-02-12).","evidence_excerpt":"On February 12, 2024, Kiromic BioPharma, Inc. (the “Company”) issued a 25% Senior Secured Convertible Promissory Note (the “Note”) to an accredited investor.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792581/000155837024001166/0001558370-24-001166-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"an accredited investor"},{"label":"Value","value":"$2,000,000"},{"label":"Effective","value":"2024-02-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}